Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00374296 · ClinicalTrials.gov registry record · Phase 2
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
A Phase 2 study, sponsored by Mirati Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT00374296 is a Phase 2 study that was terminated before completion, run by Mirati Therapeutics. The registered enrollment target is 35 participants.
The verdict
NCT00374296, a Phase 2 study, was terminated before completion, sponsored by Mirati Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
In this study, MGCD0103, a new anticancer drug under investigation, is given three times per week to elderly patients with previously untreated acute myelogenous leukemia/high risk myelodysplastic syndrome or adults with relapsed/refractory disease.
Interventions
- DRUG MGCD0103
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00374296
The ClinicalTrials.gov registry entry for NCT00374296 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MGCD0103 is the first listed.
NCT00374296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00374296 about?
NCT00374296 is a clinical study titled "MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease". In this study, MGCD0103, a new anticancer drug under investigation, is given three times per week to elderly patients with previously untreated acute myelogenous leukemia/high risk myelodysplastic syndrome or adults with relapsed/refractory disease.
What is the current status of trial NCT00374296?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2006-09. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00374296?
The interventions under investigation include: MGCD0103 (DRUG).
Who is sponsoring clinical trial NCT00374296?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.